|
1
|
Albuquerque R, López-López J, Marí-Roig A,
Jané-Salas E, Roselló-Llabrés X and Santos JR: Oral tongue squamous
cell carcinoma (OTSCC): alcohol and tobacco consumption versus
non-consumption. A study in a Portuguese population. Braz Dent J.
22:517–521. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marocchio LS, Lima J, Sperandio FF, Corrêa
L and de Sousa SO: Oral squamous cell carcinoma: an analysis of
1,564 cases showing advances in early detection. J Oral Sci.
52:267–273. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pettus JR, Johnson JJ, Shi Z, Davis JW,
Koblinski J, et al: Multiple kallikrein (KLK 5, 7, 8, and 10)
expression in squamous cell carcinoma of the oral cavity. Histol
Histopathol. 24:197–207. 2009.
|
|
4
|
Yuen PW, Lam KY, Chan AC, Wei WI and Lam
LK: Clinicopathological analysis of local spread of carcinoma of
the tongue. Am J Surg. 175:242–244. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Po Wing Yuen A, Lam KY, et al: Prognostic
factors of clinically stage I and II oral tongue carcinoma - a
comparative study of stage, thickness, shape, growth pattern,
invasive front malignancy grading, Martinez-Gimeno score, and
pathologic features. Head Neck. 24:513–520. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kasinski AL and Slack FJ: Epigenetics and
genetics. MicroRNAs en route to the clinic: progress in validating
and targeting microRNAs for cancer therapy. Nat Rev Cancer.
11:849–864. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP
and Wei WI: Mature miR-184 as potential oncogenic microRNA of
squamous cell carcinoma of tongue. Clin Cancer Res. 14:2588–2592.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu XX, Li XJ, Zhang B, et al:
MicroRNA-26b is underexpressed in human breast cancer and induces
cell apoptosis by targeting SLC7A11. FEBS Lett. 585:1363–1367.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang C, Tong J and Huang G: Nicotinamide
phosphoribosyl transferase (Nampt) is a target of microRNA-26b in
colorectal cancer cells. PLoS One. 8:e699632013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schultz NA, Dehlendorff C, Jensen BV, et
al: MicroRNA biomarkers in whole blood for detection of pancreatic
cancer. JAMA. 311:392–404. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rahbari R, Holloway AK, He M, Khanafshar
E, Clark OH and Kebebew E: Identification of differentially
expressed microRNA in parathyroid tumors. Ann Surg Oncol.
18:1158–1165. 2011. View Article : Google Scholar
|
|
14
|
Wu N, Zhao X, Liu M, et al: Role of
microRNA-26b in glioma development and its mediated regulation on
EphA2. PLoS One. 6:e162642011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ji J, Shi J, Budhu A, Yu Z, et al:
MicroRNA expression, survival, and response to interferon in liver
cancer. N Engl J Med. 361:1437–1447. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Speed N and Blair IA: Cyclooxygenase- and
lipoxygenase-mediated DNA damage. Cancer Metastasis Rev.
30:437–447. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Khan Z, Khan N, Tiwari RP, et al: Biology
of Cox-2: an application in cancer therapeutics. Curr Drug Targets.
12:1082–1093. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
19
|
Zhang YF, Zhang AR, Zhang BC, Rao ZG, et
al: MiR-26a regulates cell cycle and anoikis of human esophageal
adenocarcinoma cells through Rb1-E2F1 signaling pathway. Mol Biol
Rep. 40:1711–1720. 2013. View Article : Google Scholar
|
|
20
|
Suleyman H, Cadirci E, Albayrak A and
Halici Z: Nimesulide is a selective COX-2 inhibitory, atypical
non-steroidal anti-inflammatory drug. Curr Med Chem. 15:278–283.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Morita Y, Morita N, Hata K, et al:
Cyclooxygenase-2 expression is associated with vascular endothelial
growth factor-c and lymph node metastasis in human oral tongue
cancer. Oral Surg Oral Med Oral Pathol Oral Radiol. 117:502–510.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kono M, Watanabe M, Abukawa H, Hasegawa O,
Satomi T and Chikazu D: Cyclo-oxygenase-2 expression is associated
with vascular endothelial growth factor C expression and lymph node
metastasis in oral squamous cell carcinoma. J Oral Maxillofac Surg.
71:1694–1702. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Morita Y, Hata K, Nakanishi M, Nishisho T,
Yura Y and Yoneda T: Cyclooxygenase-2 promotes tumor
lymphangiogenesis and lymph node metastasis in oral squamous cell
carcinoma. Int J Oncol. 41:885–892. 2012.PubMed/NCBI
|
|
24
|
Wang YH, Wu MW, Yang AK, et al: COX-2 gene
increases tongue cancer cell proliferation and invasion through
VEGF-C pathway. Med Oncol. 28:S360–S366. 2011. View Article : Google Scholar
|
|
25
|
Kyzas PA, Stefanou D and Agnantis NJ:
COX-2 expression correlates with VEGF-C and lymph node metastases
in patients with head and neck squamous cell carcinoma. Mod Pathol.
18:153–160. 2005. View Article : Google Scholar
|
|
26
|
Li J, Kong X, Zhang J, Luo Q, Li X and
Fang L: MiRNA-26b inhibits proliferation by targeting PTGS2 in
breast cancer. Cancer Cell Int. 13:72013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li J, Li X, Kong X, Luo Q, Zhang J and
Fang L: MiRNA-26b inhibits cellular proliferation by targeting CDK8
in breast cancer. Int J Clin Exp Med. 7:558–565. 2014.PubMed/NCBI
|
|
28
|
Hsu CM, Lin PM, Wang YM, Chen ZJ, Lin SF
and Yang MY: Circulating miRNA is a novel marker for head and neck
squamous cell carcinoma. Tumour Biol. 33:1933–1942. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rizzo MT: Cyclooxygenase-2 in oncogenesis.
Clin Chim Acta. 412:671–687. 2011. View Article : Google Scholar
|
|
30
|
Ghosh N, Chaki R, Mandal V and Mandal SC:
COX-2 as a target for cancer chemotherapy. Pharmacol Rep.
62:233–244. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lin DT, Subbaramaiah K, Shah JP,
Dannenberg AJ and Boyle JO: Cyclooxygenase-2: a novel molecular
target for the prevention and treatment of head and neck cancer.
Head Neck. 24:792–799. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ghosh N, Chaki R, Mandal V and Mandal SC:
COX-2 as a target for cancer chemotherapy. Pharmacol Rep.
62:233–244. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kraus S, Naumov I and Arber N: COX-2
active agents in the chemoprevention of colorectal cancer. Recent
Results Cancer Res. 191:95–103. 2013. View Article : Google Scholar
|
